{
    "clinical_study": {
        "@rank": "70572", 
        "arm_group": [
            {
                "arm_group_label": "End Stage Renal Disease(ESRD)", 
                "arm_group_type": "Experimental", 
                "description": "CKD-501 will be administered to patients who have required dialysis and non-dialysis eGFR(estimate glomerular filtration rate ) is Less than 15.\nFirst, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
            }, 
            {
                "arm_group_label": "normal renal function", 
                "arm_group_type": "Active Comparator", 
                "description": "CKD-501 will be administered to normal renal function subject  who have eGFR(estimate glomerular filtration rate ) of 90 or more.\nFirst, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
            }, 
            {
                "arm_group_label": "Mild renal impairment", 
                "arm_group_type": "Experimental", 
                "description": "CKD-501 will be administered to patients who have eGFR(estimate glomerular filtration rate ) is 60 to 89 that."
            }, 
            {
                "arm_group_label": "Morderate renal impairment", 
                "arm_group_type": "Experimental", 
                "description": "CKD-501 will be administered to patients who have  eGFR(estimate glomerular filtration rate ) is 30 to 59 that."
            }, 
            {
                "arm_group_label": "severe renal impairment", 
                "arm_group_type": "Experimental", 
                "description": "CKD-501 will be administered to patients who have  eGFR(estimate glomerular filtration rate ) is 15 to 29 that."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess between the renal impaired patients and normal renal\n      function subjects comparetive evaluation to Pharmacokinetics after CKD-501 Future, When\n      prescription CKD-501 to renal impaired patient,  It will be guidelines to provide a basis of\n      instructions."
        }, 
        "brief_title": "Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects", 
        "condition": [
            "Renal Impairment", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "A Phase 1, Non-randomized, Open, Parallel-Group Clinical trial"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        All subjects:\n\n          -  Adult males or females, 20 - 65 years of age (inclusive);\n\n          -  Body mass index (BMI) range of approximately 18.5-29.9 kg/\u33a1 (inclusive);\n\n          -  Agreement with written informed consent\n\n          -  Agree to Medically acceptable method of contraception during clinical trials\n\n        Normal Renal Function subjects:\n\n          -  Matched to renal impaired patients(ESRD) in the study by age (\u00b17 years), sex and BMI\n\n          -  Medically healthy with clinically insignificant screening results (e.g., laboratory\n             profiles, medical history, EKG, physical examination);\n\n          -  eGFR \u2265 90 mL/min/1.73mE2;\n\n        Renally impaired subjects:\n\n          -  Matched to renal impaired patients(ESRD) in the study by age (\u00b17 years), sex and BMI\n\n          -  Subjects with mild renal impairment (eGFR 60-89 mL/min/1.73mE2) OR moderate renal\n             impairment (eGFR 30-59 mL/min/1.73mE2) OR severe renal impairment (eGFR 15-29\n             mL/min/1.73mE2)  OR dialysis end stage renal disease(ESRD)\n\n        Exclusion Criteria\n\n        All subjects:\n\n          -  The subject's systolic blood pressure is outside the range of 100-180mmHg, or\n             diastolic blood pressure is outside the range of 50-110mmHg\n\n          -  Repeatedly Screening ECG parameters (PR \u2265 210 mse,QRS \u2265 120 msec, QTcF \u2265 500 msec)\n\n          -  Repeatedly lab(AST >1.25xULN, ALT>1.25xULN ,Total bilirubin >1.5xULN)\n\n          -  A positive pre-study drug screen.(amphetamines, barbiturates, cocaine, opiates,\n             cannabinoids, benzodiazepin)\n\n          -  Clinically significant allergic diseases or History of thiazolidinedione class's\n             anaphylaxis reactions\n\n          -  Can not stop to be taking caffeine (caffeine > 400mg/day), drinking(alcohol > 30\n             g/day)  or severe heavy smoker(cigarette > 10 cigarettes/day) during clinical trials\n\n          -  Consumption of food which may affect study within 7 days prior to first dose of study\n             medication or taking a dietary supplement now or continued.\n\n          -  Consumption of drug which may affect study within 7 days prior to first dose of study\n             medication.\n\n          -  Previously donate whole blood within 60 days or component blood within 30 days prior\n             to first dose of study medication.\n\n          -  blood transfusion within 30 days prior to first dose of study medication.\n\n          -  Subjects with participation in another clinical trial within 60 days prior to the\n             study\n\n          -  An impossible one who participates in clinical trial by Principal investigator's\n             decision\n\n        Normal Renal Function subjects:\n\n          -  Subjects with a history of chronic disease or an acute illness within 28 days of\n             study medication administration\n\n          -  Subjects with a history of gastrointestinal disease effected study medication or\n             surgery(except appendectomy, hernia surgery)\n\n          -  Current or chronic history of liver disease or ascites or hepatic encephalopathy\n\n        Renally impaired subjects:\n\n          -  Type I diabetes, Diabetic ketoacidosis, diabetic coma or a history of coma\n             (controllable Type II diabetes including possible)\n\n          -  Uncontrollable hypertension or severe heart failure\n\n          -  require treatment with steroid or immunosuppressive drug\n\n          -  History of renal transplant or undergoing other dialysis method  except hemodialysis\n\n          -  Needs treatment for acute disease, uncontrolled other disease or diabetic\n             complications\n\n          -  Current or chronic history of liver disease or ascites or hepatic encephalopathy\n\n          -  Subjects with a history of chronic disease or an acute illness within 28 days of\n             study medication administration\n\n          -  Subjects with a history of gastrointestinal disease effected study medication or\n             surgery(except appendectomy, hernia surgery)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007941", 
            "org_study_id": "19RI113017"
        }, 
        "intervention": {
            "arm_group_label": [
                "End Stage Renal Disease(ESRD)", 
                "normal renal function", 
                "Mild renal impairment", 
                "Morderate renal impairment", 
                "severe renal impairment"
            ], 
            "description": "From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .", 
            "intervention_name": "CKD-501", 
            "intervention_type": "Drug", 
            "other_name": "Lobeglitazone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "contact": {
                "email": "phshinjg@inje.ac.kr", 
                "last_name": "Jae Kuk Shin, Ph. D. M.D", 
                "phone": "82-51-890-6709"
            }, 
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of"
                }, 
                "name": "The Inje University Busan Paik Hospital"
            }, 
            "investigator": {
                "last_name": "Jae Kuk Shin, Ph.D. M.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "5", 
        "official_title": "An Open-label, Non-randomized, Parallel-group Design Clinical Trial for Comparative Evaluation of Pharmacokinetics After CKD-501 Between Patients With Renal Impairment and Control Subjects With Normal Renal Function", 
        "overall_official": {
            "affiliation": "The Inje University Busan Paik Hospital", 
            "last_name": "Jae Kuk Shin, Ph.D. M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_outcome": {
            "description": "Blood sampling timepoint : (Day 1) 0hr, 0.33hr, 0.66hr, 1hr, 1.5hr, 2hr, 3hr, 6hr, 12hr, 24hr (Day 2)36hr (Day3)48hr- total 12 timepoints per period\nAdditional Blood sampling for unbound fraction analysis : (Day 1) 1hr, 6hr, 12hr\nUrine collection  : (Day 1)0-6hr, 6-12hr, 12-24hr (Day 2) 24-36hr, 36-48hr", 
            "measure": "The pharmacokinetic( Cmax, AUCt ) of lobeglitazone(CKD-501)  Between Renal Impaired patients and Normal Renal function subjects", 
            "safety_issue": "No", 
            "time_frame": "0-48 hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007941"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Blood sampling timepoint : (Day 1) 0hr, 0.33hr, 0.66hr, 1hr, 1.5hr, 2hr, 3hr, 6hr, 12hr, 24hr (Day 2)12hr (Day3)0hr- total 12 timepoints per period\nUrine collection  : (Day 1)0-6hr, 6-12hr, 12-24hr (Day 2) 24-36hr, 36-48hr", 
            "measure": "The pharmacokinetic( Cmax, AUCt ) of main metabolites(M7) of CKD-501  Between Renal Impaired patients and Normal Renal function subjects", 
            "safety_issue": "No", 
            "time_frame": "0-48 hrs"
        }, 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}